 |
46 Diseases |  |
10 Trials |
|
10 Trials |  |
738 News |  |
| «12345678910» |
- | ambrisentan / Generic mfg.
New P1 trial: A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects (clinicaltrials.gov) - Feb 23, 2016
P1, N=20, Not yet recruiting, Sponsor: GlaxoSmithKline
- || ambrisentan / Generic mfg.
Trial completion, Enrollment change: AMBER II: A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (clinicaltrials.gov) - Feb 22, 2016
P3, N=17, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | N=160 --> 17
- || Tyvaso (treprostinil) / United Therapeutics Corp
Trial primary completion date, Adverse events: Aspire: Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso (clinicaltrials.gov) - Feb 17, 2016
P=N/A, N=1333, Completed, Sponsor: United Therapeutics
Active, not recruiting --> Completed | N=160 --> 17 Trial primary completion date: Jul 2014 --> Dec 2014
- ||||| ambrisentan / Generic mfg.
Trial initiation date: ABS-LT: Study of Ambrisentan in Participants With Pulmonary Hypertension (clinicaltrials.gov) - Feb 3, 2016
P3, N=300, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Jul 2014 --> Dec 2014 Initiation date: Jun 2008 --> Nov 2008
- ambrisentan / Generic mfg.
Trial primary completion date: Portopulm: Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial (clinicaltrials.gov) - Nov 10, 2015
P=N/A, N=30, Recruiting, Sponsor: Tufts Medical Center
Initiation date: Jun 2008 --> Nov 2008 Trial primary completion date: Sep 2015 --> Sep 2016
- ambrisentan / Generic mfg.
Trial primary completion date: EiPAH: An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=40, Recruiting, Sponsor: Brigham and Women's Hospital
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Mar 2015 --> Dec 2015
- ||||| ambrisentan / Generic mfg.
Enrollment closed, Trial primary completion date: AMBER II: A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (clinicaltrials.gov) - Sep 21, 2015
P3, N=160, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Mar 2015 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2019 --> Sep 2015
- || ambrisentan / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: AMBER I: Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension. (clinicaltrials.gov) - Aug 31, 2015
P3, N=33, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2019 --> Sep 2015 Recruiting --> Completed | N=160 --> 33 | Trial primary completion date: Sep 2015 --> Mar 2015
- ambrisentan / Generic mfg.
Enrollment open, Trial initiation date: Ambrisentan in Single Ventricle (clinicaltrials.gov) - Aug 11, 2015
P2, N=20, Recruiting, Sponsor: Kevin Hill
Recruiting --> Completed | N=160 --> 33 | Trial primary completion date: Sep 2015 --> Mar 2015 Not yet recruiting --> Recruiting | Initiation date: Feb 2015 --> Jul 2015
- ambrisentan / Generic mfg.
Enrollment change, Trial termination: Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan (clinicaltrials.gov) - Jun 12, 2015
P4, N=3, Terminated, Sponsor: University of Texas Southwestern Medical Center
Not yet recruiting --> Recruiting | Initiation date: Feb 2015 --> Jul 2015 N=20 --> 3 | Recruiting --> Terminated; Poor enrolment
- ambrisentan / Generic mfg.
Trial completion: The Effects of Ambrisentan on Exercise Capacity in Fontan Patients (clinicaltrials.gov) - Jun 3, 2015
P4, N=28, Completed, Sponsor: Washington University School of Medicine
N=20 --> 3 | Recruiting --> Terminated; Poor enrolment Recruiting --> Completed
- ambrisentan / Generic mfg., aminophylline / Generic mfg.
Trial completion, Enrollment change: GQ02: A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude (clinicaltrials.gov) - Jun 1, 2015
P1, N=92, Completed, Sponsor: Robert J Noveck, M.D.
Recruiting --> Completed Active, not recruiting --> Completed | N=40 --> 92
- ambrisentan / Generic mfg.
Trial primary completion date, Combination therapy: Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=15, Recruiting, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed | N=40 --> 92 Trial primary completion date: Mar 2012 --> Jul 2015
- ||| Tyvaso (treprostinil) / United Therapeutics Corp
Trial completion, Adverse events: Aspire: Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso (clinicaltrials.gov) - Feb 19, 2015
P=N/A, N=1320, Completed, Sponsor: United Therapeutics
Trial primary completion date: Mar 2012 --> Jul 2015 Active, not recruiting --> Completed
- | ambrisentan / Generic mfg.
Enrollment open: EDITA: Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) (clinicaltrials.gov) - Feb 5, 2015
P2, N=38, Recruiting, Sponsor: Heidelberg University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ambrisentan / Generic mfg.
Trial primary completion date: The Effects of Ambrisentan on Exercise Capacity in Fontan Patients (clinicaltrials.gov) - Dec 10, 2014
P4, N=30, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2014 --> Mar 2015
- ambrisentan / Generic mfg.
Trial primary completion date: Portopulm: Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial (clinicaltrials.gov) - Dec 9, 2014
P=N/A, N=30, Recruiting, Sponsor: Tufts Medical Center
Trial primary completion date: Aug 2014 --> Mar 2015 Trial primary completion date: Sep 2014 --> Sep 2015
- | ambrisentan / Generic mfg.
New P2 trial: EDITA: Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) (clinicaltrials.gov) - Nov 14, 2014
P2, N=38, Not yet recruiting, Sponsor: Heidelberg University
- ambrisentan / Generic mfg.
Trial initiation date, Trial primary completion date: Ambrisentan in Single Ventricle (clinicaltrials.gov) - Nov 10, 2014
P2, N=20, Not yet recruiting, Sponsor: Kevin Hill
Trial primary completion date: Sep 2014 --> Sep 2015 Initiation date: Feb 2014 --> Feb 2015 | Trial primary completion date: Jan 2016 --> Jan 2017
- ||||||| ambrisentan / Generic mfg.
Trial completion: Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Oct 27, 2014
P3, N=134, Completed, Sponsor: GlaxoSmithKline
Initiation date: Feb 2014 --> Feb 2015 | Trial primary completion date: Jan 2016 --> Jan 2017 Active, not recruiting --> Completed
- | ambrisentan / Generic mfg., spironolactone / Generic mfg.
New P4 trial: The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (clinicaltrials.gov) - Oct 2, 2014
P4, N=30, Not yet recruiting, Sponsor: Brigham and Women's Hospital
- ||||||| ambrisentan / Generic mfg.
Trial completion, Combination therapy: AMBITION: A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Sep 29, 2014
P3, N=610, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ambrisentan / Generic mfg., aminophylline / Generic mfg.
Enrollment closed, Trial primary completion date: GQ02: A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude (clinicaltrials.gov) - Aug 21, 2014
P1, N=40, Active, not recruiting, Sponsor: Robert J Noveck, M.D.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2014 --> Sep 2014
- Tracleer (bosentan) / J&J, Roche
Trial completion, Enrollment change: SCOBA-PH: Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension (clinicaltrials.gov) - Aug 11, 2014
P4, N=32, Completed, Sponsor: University of Alabama at Birmingham
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2014 --> Sep 2014 Active, not recruiting --> Completed | N=110 --> 32
- ambrisentan / Generic mfg.
Trial primary completion date: EiPAH: An Open-Label Uncontrolled Study of the Safety and Efficacy of Ambrisentan in Participants With Exercise-Induced Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=40, Recruiting, Sponsor: Brigham and Women's Hospital
Active, not recruiting --> Completed | N=110 --> 32 Trial primary completion date: Dec 2013 --> Mar 2015
- ||| ambrisentan / Generic mfg.
Enrollment closed, Trial primary completion date: ATPAHSS: A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (clinicaltrials.gov) - Jul 17, 2014
P4, N=63, Active, not recruiting, Sponsor: United Therapeutics
Trial primary completion date: Dec 2013 --> Mar 2015 Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Nov 2014
- || Tyvaso (treprostinil) / United Therapeutics Corp
Enrollment closed, Adverse events: Aspire: Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso (clinicaltrials.gov) - Jul 16, 2014
P=N/A, N=1320, Active, not recruiting, Sponsor: United Therapeutics
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Nov 2014 Recruiting --> Active, not recruiting
- ||||| ambrisentan / Generic mfg.
Enrollment closed: Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Jun 17, 2014
P3, N=120, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||| ambrisentan / Generic mfg.
Enrollment open: AMBER II: A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (clinicaltrials.gov) - Apr 9, 2014
P3, N=160, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ambrisentan / Generic mfg.
New P2 trial: Ambrisentan in Single Ventricle (clinicaltrials.gov) - Mar 4, 2014
P2, N=20, Not yet recruiting, Sponsor: Kevin Hill
- ambrisentan / Generic mfg.
Enrollment change: (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF (clinicaltrials.gov) - Feb 26, 2014
P3, N=494, Terminated, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting N=660 --> 494
- ambrisentan / Generic mfg.
Trial completion: Drug Combination on Exercise Performance at High Altitude (clinicaltrials.gov) - Feb 25, 2014
P2/3, N=30, Completed, Sponsor: University of Montana
N=660 --> 494 Not yet recruiting --> Completed
- ||||||| ambrisentan / Generic mfg.
Trial completion: ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Feb 22, 2014
P3, N=372, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Completed No longer recruiting --> Completed
- |||| ambrisentan / Generic mfg.
Trial completion: Study of BSF 208075 Evaluating Exercise Capacity in Patients With Pulmonary Arterial Hypertension (clinicaltrials.gov) - Feb 22, 2014
P2, N=60, Completed, Sponsor: Gilead Sciences
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||| ambrisentan / Generic mfg.
Enrollment closed, Combination therapy: AMBITION: A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Jan 8, 2014
P3, N=614, Active, not recruiting, Sponsor: GlaxoSmithKline
No longer recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| ambrisentan / Generic mfg.
Enrollment closed: ABS-LT: Study of Ambrisentan in Participants With Pulmonary Hypertension (clinicaltrials.gov) - Nov 24, 2013
P3, N=300, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
- |||||| ambrisentan / Generic mfg.
Enrollment open: AMBER I: Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension. (clinicaltrials.gov) - Nov 20, 2013
P3, N=160, Recruiting, Sponsor: GlaxoSmithKline
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| ambrisentan / Generic mfg.
Trial completion: VOLT: An Observational Study For Ambrisentan (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=800, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Recruiting --> Completed
- ambrisentan / Generic mfg.
New P4 trial: The Effects of Ambrisentan on Exercise Capacity in Fontan Patients (clinicaltrials.gov) - Oct 27, 2013
P4, N=30, Recruiting, Sponsor: Washington University School of Medicine
- ||||| ambrisentan / Generic mfg.
Trial initiation date: AMBER II: A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (clinicaltrials.gov) - Sep 25, 2013
P3, N=160, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed Initiation date: Jul 2013 --> Dec 2013
- | ambrisentan / Generic mfg.
Trial suspension: Efficacy and Safety of Ambrisentan in Children 8-18yrs (clinicaltrials.gov) - Sep 11, 2013
P2, N=66, Suspended, Sponsor: GlaxoSmithKline
Initiation date: Jul 2013 --> Dec 2013 Recruiting --> Suspended
- ambrisentan / Generic mfg., aminophylline / Generic mfg.
Enrollment open: GQ02: A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude (clinicaltrials.gov) - Sep 4, 2013
P1, N=40, Recruiting, Sponsor: Thies Schroeder
Recruiting --> Suspended Not yet recruiting --> Recruiting
- ambrisentan / Generic mfg.
New P2/3 trial: Drug Combination on Exercise Performance at High Altitude (clinicaltrials.gov) - Jul 16, 2013
P2/3, N=30, Completed, Sponsor: University of Montana
- |||||||||| ambrisentan / Generic mfg.
New P3 trial: AMBER II: A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (clinicaltrials.gov) - Jul 7, 2013
P3, N=160, Recruiting, Sponsor: GlaxoSmithKline
- |||||||||| ambrisentan / Generic mfg.
New P3 trial: AMBER I: Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension. (clinicaltrials.gov) - Jun 20, 2013
P3, N=160, Recruiting, Sponsor: GlaxoSmithKline
- Tracleer (bosentan) / J&J, Roche
Trial completion: ERAATH: Characterization and Detection of Prolonged Endothelin Receptors Antagonists Administration (clinicaltrials.gov) - May 6, 2013
P2/3, N=30, Completed, Sponsor: Center for Health, Exercise and Sport Sciences, Serbia
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || ambrisentan / Generic mfg.
New P3 trial: Study of a drug to treat chronic thromboembolic pulmonary hypertension (CTEPH) (EUDRACT) - Apr 8, 2013
P3, N=275, Ongoing, Sponsor: GlaxoSmithKline, S.A.`GlaxoSmithKline Research & Developement Ltd
- | ambrisentan / Generic mfg.
Trial completion: Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet (clinicaltrials.gov) - Mar 21, 2013
P=N/A, N=20, Completed, Sponsor: Soumya Chatterjee
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| ambrisentan / Generic mfg.
New P3 trial: Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Mar 7, 2013
P3, N=120, Recruiting, Sponsor: GlaxoSmithKline
- || ambrisentan / Generic mfg.
New P3 trial: An extension study of a drug to treat Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (EUDRACT) - Mar 5, 2013
P3, N=275, Ongoing, Sponsor: GlaxoSmithKline, S.A.`GlaxoSmithKline Research & Developement Ltd